Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5286173 | 0.95 | SLC9A1 (0.45) | SLC9A1MAOAHCAR3GRM2ALDH1A1 | |
| SCHEMBL5276804 | 0.91 | SLC9A1 (0.45) | SLC9A1MAOAHCAR3GRM2ALDH1A1 | |
| SCHEMBL5278890 | 0.91 | SLC9A1 (0.42) | SLC9A1MAOAHCAR3HSD11B1GRM2 | |
| SCHEMBL5273967 | 0.87 | MAOA (0.40) | SLC9A1MAOAHSD11B1GRM2ALDH1A1 | |
| SCHEMBL5274763 | 0.87 | SLC9A1 (0.42) | SLC9A1MAOAHCAR3GRM2ALDH1A1 | |
| SCHEMBL5279549 | 0.85 | SLC9A1 (0.46) | SLC9A1MAOAHCAR3GRM2ALDH1A1 | |
| SCHEMBL9944053 | 0.81 | SLC9A1 (0.44) | SLC9A1MAOAHCAR3HSD11B1GRM2 | |
| SCHEMBL5279067 | 0.81 | SLC9A1 (0.43) | SLC9A1MAOAHCAR3GRM2ALDH1A1 | |
| SCHEMBL5275648 | 0.81 | MAOA (0.51) | SLC9A1MAOAHSD11B1MAOB | |
| SCHEMBL5277913 | 0.80 | SLC9A1 (0.42) | SLC9A1HCAR3GRM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632901-B1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20210317074-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-10-14 | — | — | US | disclosed |
| US-11034647-B2 | Histone acetyltransferase activators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-15 | — | — | US | disclosed |
| US-10640457-B2 | Histone acetyltransferase activators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200115325-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-16 | — | — | US | disclosed |
| EP-3632901-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2509590-B1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20130121919-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2509590-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011072243-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034647-B2 | Histone acetyltransferase activators and uses thereof | EP300, KAT2A, NAA40 | SLC9A1 1774/4885MAOA 938/4885HCAR3 2670/4885 |
| US-20200115325-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | SLC9A1 1774/4885MAOA 938/4885HCAR3 2670/4885 |
| US-10640457-B2 | Histone acetyltransferase activators and uses thereof | EP300, KAT2A, NAA40 | SLC9A1 1774/4885MAOA 938/4885HCAR3 2670/4885 |
| US-20210317074-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | SLC9A1 1774/4885MAOA 938/4885HCAR3 2670/4885 |
| US-20130121919-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | SLC9A1 1774/4885MAOA 938/4885HCAR3 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.